Lexicon Pharmaceuticals (LXRX) Non-Current Assets (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) posted quarterly Non-Current Assets of $82.8 million for Q1 2026, up 59.62% year-over-year from $51.9 million in Q1 2025, and little changed quarter-over-quarter from $83.1 million in Q4 2025.
Lexicon Pharmaceuticals (LXRX) Non-Current Assets (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported Non-Current Assets for 17 consecutive years, with $82.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 59.62% year-over-year to $82.8 million; the TTM figure through Mar 2026 stood at $329.8 million (up 57.7% YoY), while the FY2025 annual figure was $83.1 million, up 59.1% from the prior year.
- Non-Current Assets held at $82.8 million in Q1 2026 per LXRX's latest filing, from $83.1 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $83.4 million in Q3 2025 and bottomed at $47.4 million in Q2 2022.
- Historically, Non-Current Assets has averaged $59.1 million across 5 years, with a median of $52.9 million in 2023.
- Annual changes were most pronounced in 2022 — Non-Current Assets dropped 2.04% — and 2026, when it soared 59.62%.
- Lexicon Pharmaceuticals' Non-Current Assets stood at $53.4 million in 2022, then slipped by 1.03% to $52.9 million in 2023, then dropped by 1.24% to $52.2 million in 2024, then soared by 59.1% to $83.1 million in 2025, then dropped by 0.37% to $82.8 million in 2026.
- Business Quant data shows LXRX's Non-Current Assets at $82.8 million in Q1 2026, $83.1 million in Q4 2025, and $83.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Lexicon Pharmaceuticals | 1.04 Bn | 846.13 Mn | 653,000.00 | 53.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 53.48 Mn |
| Mar 31, 2026 | 82.79 Mn |
| Dec 31, 2025 | 83.09 Mn |
| Sep 30, 2025 | 83.40 Mn |
| Jun 30, 2025 | 80.50 Mn |
| Mar 31, 2025 | 51.87 Mn |
| Dec 31, 2024 | 52.23 Mn |
| Sep 30, 2024 | 52.52 Mn |
| Jun 30, 2024 | 52.51 Mn |
| Mar 31, 2024 | 52.57 Mn |
| Dec 31, 2023 | 52.88 Mn |
| Sep 30, 2023 | 53.11 Mn |
| Jun 30, 2023 | 53.00 Mn |
| Mar 31, 2023 | 53.17 Mn |
| Dec 31, 2022 | 53.43 Mn |
| Sep 30, 2022 | 52.62 Mn |
| Jun 30, 2022 | 47.43 Mn |
| Mar 31, 2022 | 47.75 Mn |
| Dec 31, 2021 | 47.99 Mn |
| Sep 30, 2021 | 48.33 Mn |